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SUMMARY
Myalgic encephalomyelitis is a complex, multisystem disease with chronic course significantly affecting 
patients’ quality of life. Physical and mental exertion intolerability, muscle pain, and sleep problems are 
the main features accompanied often with cognitive inefficacy and vegetative symptoms. Prevalence is 
7–3000 per 100,000 adults. It is estimated that 90% of the patients are misdiagnosed. Pathogenesis is still 
only speculative but current research points to disturbances in the immunological system, inflammatory 
pathways, autonomic and central nervous system, muscle and mitochondria, as well as alterations of gut 
microbiota and gut permeability. The onset is typically acute, following an infectious disease. Exertional 
intolerance lasting for more than six months is an important diagnostic factor. The core features must 
be moderate to severe and present at least 50% of the time. Diagnostic criteria should be fulfilled and 
differential diagnosis should be made to exclude other potential pathological conditions or to diagnose 
comorbidities. Brain magnetic resonance imaging morphometry has shown gray matter atrophy in oc-
cipital lobes bilaterally, right angular gyrus, and the posterior division of the left parahippocampal gyrus, 
consistent with memory problems and potentially with impairment of visual processing. Treatment is 
still symptomatic and of partial benefit. Symptomatic treatment can include medications for controlling 
pain and sleep problems, graded exercise and cognitive behavioral therapy. Larger controlled trials are 
needed to shed more light on this challenging condition.
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INTRODUCTION
Myalgic encephalomyelitis (ME) with chronic 
fatigue syndrome (CFS) (ME/CFS) or systemic 
exertion intolerance disease (SEID)is a multi-
faceted condition involving muscular, nervous, 
hormonal, and immune systems [1, 2]. Patients 
have difficulties with sleep and attention, ex-
perience pain and dizziness, and have extreme 
fatigue not accountable to any other medical 
condition [3]. ME can be incapacitating and 
often affects activities of daily living, some-
times making patients immobile (up to 25%). 
Syndrome is typically chronic, with the onset 
between 40 and 60 years, but it can begin at any 
age. Women are prone to ME/CFS more than 
men. This is an overlapping domain of rheuma-
tology, neurology, and psychiatry. Prevalence 
of ME/CFS is 0.1–2.2% [4]. It is estimated that 
90% of the patients are misdiagnosed. Physi-
cians are often not educated in ME/CFS and 
there is no confirmatory test. 
CLINICAL PICTURE
Symptoms of ME/CFS can develop suddenly or 
gradually [5]. Sometimes it starts as a flu-like 
disease or after an infection (viral, bacterial, 
or parasitic) [6]. Involved clinical domains are 
multiple and can be neurological, cognitive, im-
mune, autonomic, post exertional malaise, and 
pain [7]. These patients also face an increased 
risk for developing diabetes, cardiovascular 
disease, and thyroid disease.
Patients are fatigued, do not improve with rest 
and are worse on attempt of physical or mental 
activity (post-exertional malaise – PEM; SEID). 
There is often working incapacity, secondary al-
coholism, and inability to participate in family 
and social life. Before the onset of CFS/ME, most 
patients are healthy and active [1].
Typically, there are muscle or joint pains, 
memory, concentration, and information pro-
cessing speed problems. Perception, speech, 
motor functions, and intelligence are not in-
volved. Patients complain of sore throat, head-
aches, unrefreshing sleep, feeling dizzy, and are 
generally unwell. Some patients have digestive 
problems, night sweats, or may be intolerant to 
some foods, chemicals, or noise [5].
People can have difficulties to sit or walk, 
and some might be bedridden (up to 25%). The 
other group of patients, in contrast, have pre-
served functional capacities, but the majority 
have at least some difficulty at work, in family 
life and/or at school. Approximately 75% of 
the patients are unable to participate in their 
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professional activities. Symptoms often fluctuate during 
the day or on various days, last more than six months, and 
cannot be explained by any other disease [1]. Objectively 
enlarged lymph nodes can be found in the neck or arm-
pits. Sometimes there are palpitations and irregular heart 
beat. ME/CFS often lead to depression, social isolation, 
impairment of activities of everyday living and incapacity 
for work. 
Younger children with ME/CFS have a more equal sex 
representation compared to adolescents and adults, shorter 
duration of symptoms, less distinct disability and fatigue, 
and are less prone to cognitive symptoms, but more often 
complain of a sore throat [8]. Adolescents less often have 
palpitations, dizziness, malaise, pain, anxiety, and tender 
lymph nodes, but more often headaches and comorbid 
depression than adults [8]. 
ETIOLOGY
Etiology of ME/CFS is not known but known risk fac-
tors are age (40s and 50s), female sex, psychological stress, 
childhood trauma, lower middle education, low physical 
fitness, preexisting psychological illness (depression, anxi-
ety), and allergies [1]. Epstein–Barr virus or human her-
pesvirus-4 (HHV-4) can cause infectious mononucleosis 
that causes syndrome that fulfills criteria for ME/CFS in 
substantial number of affected individuals [9]. Other viral 
infections that can lead to chronic fatigue are HHV-6 and 
mouse leukemia viruses. Also, there is a possibility of some 
bacterial infections. 
The patients with ME/CFS have slight impairment of 
the immune system: changes in cytokine and immuno-
globulin levels, T- and B-cell phenotype, and a decrease of 
natural killer cell cytotoxicity, but also increased certain 
autoantibodies’ levels [10, 11]. Some authors hypothesize 
about the possibility of ME/CFS being an autoimmune 
disease as there are autoantibodies to some neurotrans-
mitter receptors [10]. Autoimmunity can be triggered by 
infectious agents and/or stress, and immune deficiencies 
leading to other pathological mechanisms. Increased 
permeability of intestinal and blood–brain barriers can 
lead to the penetration of antibodies from the general 
circulation into the brain, with potential brain tissue au-
toimmune lesions [9].
So far, many autoantibodies have been detected, mainly 
those targeting nuclear structures (antinuclear antibodies, 
nuclear envelope, reticulated speckles, etc.), membrane 
structures (phospholipids, cardiolipin, phosphatidylserine, 
gangliosides), neurotransmitter receptors and neurotrans-
mitters (MAchR, M1 AChR, M3/4 AchR, 5-hydroxytryp-
tamine) and other antigens [10]. Immunological activation 
forces change to aerobic glycolysis in order to keep necessary 
energy levels, leading to maintenance of chronic inflamma-
tion with mitochondrial dysfunction and extreme fatigue. 
Some hormonal imbalances can be found in function 
of hypothalamus, pituitary, and adrenal glands, but its sig-
nificance is not known. Many deficiencies of the B complex 
vitamins are manifested by malaise and cognitive decline 
and are of substantial prevalence, but these etiological pos-
sibilities need large studies [12, 13].
Genetic factors may play some role in the etiology of 
ME/CFS. Twin studies show increased predisposition for 
the condition and there are also studies linking genetic 
factors and infection [14]. 
ME/CFS is also characterized by increased measures of 
oxidative stress while antioxidant potential is decreased. 
This process leads to impaired lipid-based signaling systems 
of S-palmitoylation and of omega-3 polyunsaturated fatty 
acids [15]. Nitric oxide/superoxide cycle is also involved in 
cardiac failure and might be the crucial mechanism of in-
creased fatigue [16]. Overproduction of nitric oxide leads to 
increased levels of superoxide with consequent depletion of 
adenosine triphosphate (ATP) and activation of excitatory 
neurotransmitter N-methyl-D-aspartate, which is followed 
by an increase of intracellular calcium that continues the 
vicious cycle with increased activity of nitric oxide. Chronic 
activation of nuclear factor kappa B (NFκB) is supposed to 
be present in ME/CFS, and vitamin D3 supplementation 
could suppress the activation of NFκB [16]. 
PATOGENESIS
Pathogenesis of ME/CFS is still only speculative but cur-
rent research points to disturbances in immunological 
system, inflammatory pathways, autonomic and central 
nervous system, muscles, mitochondria, gut microbiota, 
and permeability [1, 17]. Infectious mechanisms also may 
play a role in ME/CFS as well as other factors that can 
initiate similar pathological cascades [17]. 
Extreme fatigue in ME/CFS might be the result of ener-
gy production disturbances leading to exertion intolerance 
[2]. Some evidence leads to autonomic nervous system 
dysfunction, such as orthostatic hypotension or tachy-
cardia, at least in some ME/CFS patients [18]. Metabolic 
syndrome might not be the cause but the result of fatigue 
and the lack of physical activity [2].
One study recognized nine biochemical factors com-
mon to both male and female ME/CFS patients but not 
to healthy controls with an apparent diagnostic accuracy 
of more than 90% [19]: a decrease in sphingolipid, glyco-
sphingolipid, phospholipid, purine, microbiome aromatic 
amino acid, branched-chain amino acid metabolites, fla-
vine adenine nucleotide, and lathosterol. These changes 
constitute the hypometabolic profile of ME/CFS. 
ME/CFS has been linked with mitochondrial dysfunc-
tion, damage of adenosine monophosphate-activated pro-
tein kinase, oxidative stress, and skeletal muscle cell aci-
dosis, which correlate with core symptoms such as fatigue, 
exercise intolerance, and myalgia [2]. Contrary to known 
mitochondrial diseases, in ME/CFS there is no mutation 
in either nuclear or mitochondrial DNA [20]. Also, there 
is no ATP reduction. Findings of muscle biopsies from 
subjects with ME/CFS have shown signs of mitochondrial 
degeneration and oxidative damage [2].
There are some indications of impaired function of 
hypothalamic–hypophyseal–adrenal axis [21]. Microglia 
Pavlović D. M. et al.
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probably have an important role in ME/CFS. It has been 
proposed that microglia might be activated by various fac-
tors such as immune changes, stress, etc., via the stimu-
lation of hypothalamic mast cells with consequent focal 
neuroinflammation and disturbed homeostasis with mi-
tochondrial dysfunction [2]. 
Some studies advocate for a role for microglia and astro-
cytes of immunologically induced CFS, so that the infec-
tion causes sequential signaling such as increased blood–
brain barrier permeability, secretion of IL-1β, upregulation 
of the serotonin transporter (5-HTT) in astrocytes, reduc-
ing extracellular serotonin (5-HT) levels and less activation 
of 5-HT1A receptor subtype [22]. This etiopathogenetic 
assumption has found clinical confirmation in achieving 
positive therapeutic effects using antidepressants from the 
group of selective serotonin reuptake inhibitors. 
Neuroimaging in ME/CFS shows more diffuse activa-
tion patterns than controls on attention tests, sometimes 
structural abnormalities in the brain stem with signs of 
inflammation, reduction in the serotonin 1A receptor 
binding, particularly in the hippocampus bilaterally, and 
reduced serotonin transporters density in the rostral an-
terior cingulate [23]. Some studies also showed regional 
abnormalities but with inconsistent locations and wide-
spread disruption of the autonomic nervous system [24].
Clinical pictures of ME/CFS and d-lactic acidosis are 
overlapping and there is evidence of d-lactate-producing 
bacteria dysbiosis [25]. Both conditions have neurologi-
cal disturbances caused by microbiota–gut–brain system 
dysfunction. D-lactic acidosis is an acute condition causing 
encephalopathy, while ME/CFS is a chronic state with pos-
sible subclinical levels of d-lactate, making the two entities 
possibly the parts of the same continuum [25]. 
DIAGNOSIS
Diagnosis of ME/CFS is made on the clinical grounds and 
by exclusion of other medical conditions with no specific 
diagnostic test [1]. Current diagnostic criteria for ME/CFS 
proposed by the United States Centers for Disease Control 
and Prevention are presented in Table 1 [5]. The onset of 
ME/CFS is typically acute following an infectious disease. 
Exercise intolerance lasting more than six months is an im-
portant diagnostic factor. Fatigue is not alleviated with rest. 
Sleep problems are always present. Optional symptoms are 
orthostatic intolerance and/or memory and concentration 
problems. Core clinical features must be moderate to se-
vere and present at least 50% of the time.
Documenting PEM is very important and is defined as 
a “collapse” after previously tolerated physical and psychic 
exertion, sometimes during even mild everyday activities 
[26]. Recommended additional investigations in ME/CFS 
depending on the symptoms are the following: chest X-ray, 
electrocardiogram, tilt table test for autonomic function, 
ACTH challenge test or cortisol stimulation test, para-
thyroid hormone, estradiol, follicle-stimulating hormone, 
gastroscopy, colonoscopy, gliadin, endomysial antibodies, 
infectious disease screen including HIV, hepatitis, Lyme 
disease, Q fever, microbiology of stools, urine, genitals 
and respiratory tract, antinuclear antibodies, immuno-
globulins, functional antibodies and subsets of lympho-
cytes, magnetic resonance imaging of the brain, overnight 
polysomnography with multiple sleep latency test, and 
cystoscopy [6].
There is still not a unique set of biomarkers that would 
help in diagnosing ME/CFS. There are many proposed and 
studied compounds but with yet uncertain significance – 
precise measures of potentially elevated d-lactic acid [25]. 
Human herpesviruses (HHV-1–8, including HHV-6A and 
HHV-6B) and Epstein–Barr virus are associated with ME/
CFS, but studies have not shown significant differences 
between patients and healthy controls [27]. 
DIFFERENTIAL DIAGNOSIS
Differential diagnosis of ME/CFS is quite wide and consists 
of the following [5, 26]:
•  Infectious diseases: tick-borne diseases – Lyme dis-
ease (including neuroborreliosis) etc., mononucleosis 
i.e. Epstein–Barr virus, parvovirus, HIV infection and 
AIDS, influenza, tuberculosis, hepatitis B and C, Giar-
dia, West Nile virus, Q fever, Valley fever, syphilis;
•  Psychiatric disorders: anxiety, depression and bipolar 
disorder, alcohol and substance abuse, schizophrenia, 
delusional disorders, dementia, anorexia/bulimia ner-
vosa; sleep apnea;
•  Rheumatological diseases: fibromyalgia, polymyalgia 
rheumatica, Sjögren’s syndrome, giant-cell arteritis, 
polymyositis, dermatomyositis, systemic lupus, rheu-
matoid arthritis;
•  Neurological diseases: parkinsonism, multiple scle-
rosis (MS), myasthenia gravis, vitamin B12 deficiency, 
cerebrospinal fluid leak, Chiari malformation, sleep 
apnea, narcolepsy, periodic limb movement disorder, 
malformation, traumatic brain injury, spinal stenosis, 
craniocervical instability, seizures;
•  Endocrine/metabolic diseases: diabetes mellitus, 
hypothyroidism, hyperthyroidism, thyroiditis, Addi-
son’s disease, adrenal insufficiency, Cushing’s disease, 
hypercalcemia;
•  Cardiovascular disorders: cardiomyopathy, conges-
tive heart failure, coronary artery, disease, pulmonary 
hypertension, valvular heart disease, arrhythmias;
Table 1. Current diagnostic criteria for myalgic encephalomyelitis with 
chronic fatigue syndrome proposed by the Centers for Disease Control 
1
Significantly lowered ability to participate in activities that 
were routine before the onset of the condition, and persisting 
more than six months
2
Physical or mental activity causing worsening symptoms that 




Additionally, one of the two:
• Difficulty with thinking and memory
• Worsening of problems with standing or sitting
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•  Gastrointestinal disorders: coeliac disease, food aller-
gy or intolerances, inflammatory bowel diseases, small 
intestinal bacterial overgrowth, chronic hepatitis;
• Miscellaneous: anemia, iron overload, various malig-
nancies (primary and secondary), sinusitis, allergic rhinitis, 
the effect of some drugs, chronic obstructive pulmonary 
disease, asthma, end-stage kidney disease, severe obesity 
(BMI > 40), overwork / burnt out syndrome, athletic over-
training, heavy metals toxicity (e.g. lead, mercury), etc.
ME/CFS can have remitting course that must be distin-
guished from MS as they have some overlapping symptoms 
[28]. These are fatigue, cognitive problems, physical dis-
ability, etc. However, MS patients do not have, unlike those 
with ME/CFS, tender lymph nodes and flu-like symptoms, 
are younger, more likely to be married, less Caucasian, 
and with less disability [28]. Contrary to depression, ME/
CFS does not have anhedonia, low motivation, and guilt.
A closely related problem are comorbidities, so diag-
nostic procedure is not a mere excluding process. Various 
diseases can coexist with ME/CFS, so they also have to be 
diagnosed and treated [26].
TREATMENT
There is no causal cure for ME/CFS. Symptomatic treat-
ments can include medications for controlling pain and 
sleep problems, graded exercise therapy, which is con-
troversial, and cognitive behavioral therapy (CBT) [26]. 
Many medications have been tried but without proved 
therapeutic effects, so they are used off label [29]. Anti-
convulsants, mostly gabapentin and pregabalin, are pre-
scribed to alleviate pain and sleep disturbances, but are 
most effective for neuropathic pain [1]. Antidepressants 
(nefazodone, mirtazapine, sertraline, amitriptyline, and 
others) can be administered in cases of depression, anxiety 
and sleep problems, but have a plethora of side effects and 
interact with many other drugs, so one should be very 
careful in prescribing these medications [30]. Alternative 
to antidepressants is CBT. In patients with most severe and 
therapy-resistant pain, narcotic medicines are prescribed, 
usually tramadol, codeine, etc., for a short period to avoid 
risk of addiction [31].
In line with the proposed immune and viral etiology, 
immunomodulatory drugs are given, such as rintatolimod 
and rituximab, which supposedly improve exercise capac-
ity, cognition, and the quality of life, but the studies are of 
insufficient quality and with equivocal proof of the drug’s 
efficacy and safety [1]. Steroid treatment is known for its 
immunosuppressive properties but studies did not show 
any substantial benefit [32]. 
Important aspect of CFS/ME treatment is the use of 
nutritional supplements in patients with biochemically 
proven deficiencies [1]. Multivitamin/multimineral tab-
lets containing antioxidant compounds (e.g. alpha-lipoic 
acid, vitamin C, and vitamin E) showed some promise in 
a study in women with ME/CFS [33]. In prescribing some 
supplements, laboratory follow up is necessary [34, 35]. 
General fatigue is one of the main symptoms in vitamin 
B12 deficiency [34, 35, 36]. There is substantial difference 
in determining “normal” levels of vitamin B12 in the blood 
among studies, and blood levels are not a good measure 
of tissue B12 status [34]. Also, different preparations and 
administration routes further complicate assessment of 
B12 supplementation in such a controversial entity as CFS/
ME. Experience with injections of methylcobalamin in 
patients with CFS/ME in combination with folic acid is 
positive [37].
Combination of coenzyme Q10 and nicotinamide ad-
enine dinucleotide is an antioxidant treatment that also 
improves mitochondrial function in CFS/ME due to in-
creased ATP production [38]. Essential fatty acids adminis-
tration in CFS/ME showed improvement in only one study, 
while others did not find any improvement [39]. 
Treating gut dysbiosis i.e. antibiotics targeting Strep-
tococcus genus is a hypothetical therapy for neurological 
symptoms in ME/CFS, not much explored so far [40]. 
Treatment protocol of a recent study included a four-week 
treatment with alternate weeks of erythromycin as ethyl 
succinate salt 400 mg twice daily and probiotic (d-lactate 
free multistrain probiotic, 5 × 1010 cfu) twice daily [40]. 
Significant improvement was noted in sleep, attention, 
speed of processing information, cognitive flexibility, 
verbal memory and fluency, with more impact in males. 
Level of fatigue, mood, and urine d:l lactate ratio did not 
change with medication. 
PROGNOSIS
A systematic review described improvement and occupa-
tional outcomes of people with CFS found that the me-
dian full recovery rate was 5% with the range 0–31%, and 
the median proportion of patients who improved during 
follow-up was 39.5%, range 8–63% [41]. Return to work at 
follow-up ranged 8–30% in relevant studies. In five studies, 
a worsening of symptoms during the period of follow-up 
was detected in 5–20% of participants. A good outcome 
was associated with less fatigue severity at baseline. Other 
factors occasionally, but not consistently, related to the 
outcome, included age at onset, and attributing illness 
to a psychological cause and/or having a sense of control 
over symptoms [41]. Although clinical picture is chronic, 
most people get better over time with some rest symptoms. 
Younger age is a favorable prognostic factor. 
CONCLUSION
CFS/ME is a complex, multisystem disease of chronic 
course with serious consequences on patients’ quality of 
life. Physical and mental exertion intolerability, muscle 
pain, and sleep problems are the main features often ac-
companied by cognitive inefficacy and vegetative symp-
toms. Etiology and pathophysiology are not known but 
there are many theories based on multiple findings of in-
volvement of immune, endocrine/metabolic, biochemical, 
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and other mechanisms. There are numerous comorbidities, 
and differential diagnosis is often complicated. Treatment 
is still symptomatic and of partial benefit, with many drugs 
of various classes and nonpharmacological measures rou-
tinely used. Larger controlled trials are needed to shed 
more light on this challenging condition.
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САЖЕТАК
Мијалгични енцефаломијелитис је сложено, мултисистем-
ско обољење са хроничним током које значајно утиче на 
квалитет живота болесника. Слаба толеранција на физички 
и ментални напор, болови у мишићима и проблеми са спа-
вањем главне су одлике и често су праћене когнитивном 
неефикасношћу и вегетативним симптомима. Превален-
ција је 7–3000 на 100.000 одраслих. Процењује се да је 90% 
ових болесника погрешно дијагностиковано. Патогенеза 
је и даље само спекулативна, али тренутна истраживања 
указују на поремећаје у имунолошком систему, инфламатор-
ном одговору, аутономном и централном нервном систему, 
мишићима и митохондријама, као и промене микробиоте и 
пропустљивости црева. Почетак болести је типично акутан 
и прати инфективну болест. Нетолеранција напора која траје 
дуже од шест месеци важан је дијагностички критеријум. 
Основне карактеристике морају бити умерене до тешке и 
присутне најмање 50% времена. Искључивање других мо-
гућих патолошких стања или коморбидитетних дијагноза 
захтева задовољавање дијагностичких критеријума и ди-
ференцијално дијагностичко сагледавање. Морфометријска 
снимања мозга магнетном резонанцом показала су атрофију 
сиве масе у окципиталним режњевима билатерално, десном 
ангуларном гирусу и постериорном левом парахипокампал-
ном гирусу, што може довести до проблема са памћењем и 
оштећења визуелне обраде информација. Лечење је и даље 
симптоматско и само делимично успешно. Симптоматски 
третман може да укључује лекове за контролу бола и про-
блема са спавањем, дозирану физичку активност и когни-
тивно-бихевиоралну терапију. Потребне су веће студије да 
би се разјаснило ово медицинско стање.
Кључне речи: миjалгични енцефаломијелитис; синдром 
хроничног умора; слабост после напора
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